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Abstract
Purpose—To systematically examine trends and applications of the disease risk score (DRS) as
a confounder summary method.
Methods—We completed a systematic search of MEDLINE and Web of Science® to identify all
English language articles that applied DRS methods. We tabulated the number of publications by
year and type (empirical application, methodological contribution, or review paper) and
summarized methods used in empirical applications overall and by publication year (<2000,
≥2000).
Results—Of 714 unique articles identified, 97 examined DRS methods and 86 were empirical
applications. We observed a bimodal distribution in the number of publications over time, with a
peak 1979-1980, and resurgence since 2000. The majority of applications with methodological
detail derived DRS using logistic regression (47%), used DRS as a categorical variable in
regression (93%), and applied DRS in a non-experimental cohort (47%) or case-control (42%)
study. Few studies examined effect modification by outcome risk (23%).
Conclusion—Use of DRS methods has increased yet remains low. Comparative effectiveness
research may benefit from more DRS applications, particularly to examine effect modification by
outcome risk. Standardized terminology may facilitate identification, application, and
comprehension of DRS methods. More research is needed to support the application of DRS
methods, particularly in case-control studies.
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Epidemiologic analyses often require investigators to control for many measured
confounding variables. Restriction, stratification and matching allow for easily interpretable
analysis, yet become complex as the number of variables for adjustment increase.1
Adjustment using multivariable regression techniques has thus become a standard method to
control for confounding. In addition to conventional multivariable regression methods that
include the exposure and potential confounding variables in a single outcome model, two
methods of confounder summary score techniques have been proposed: the exposure
propensity score (EPS), and the disease risk score (DRS).2-8 EPS reflect patients’ exposure
probability conditional on measured confounders. This confounder summary score can then
be used in place of the individual confounding variables in conventional adjustment
methods, such as: matching, stratification, weighting, restriction, or as a covariate in the
outcome model.3,4,9 Use of EPS has increased exponentially since its introduction in
1983.2,3 However, EPS is limited when exposure is rare and can be complicated when
studying multiple exposures or multiple exposure levels.
The DRS is the prognostic analogue of the EPS, derived based on the predicted risk of
disease outcome and was first proposed methodologically in 1976.5 Early simulation work
published in 1979 concluded that the DRS method may overestimate the effect of
confounders and thus bias results.10 A subsequent simulation published in 1989 concluded
that overestimation of confounders may be rare, particularly when applying the DRS as a
categorical variable.11 Recent evidence also identifies that in the setting of a large number of
exposed individuals and outcomes, conventional multivariable regression, EPS and DRS
methods yield similar results provided covariates are not highly correlated with
exposure.3,6-8,12 Although the intention of EPS and DRS in summarizing confounders into a
single summary score is similar, the logic behind the methods is distinct. EPS model the
treatment selection process to balance treatment determinants, similar in concept to
randomization in clinical trials. DRS do not share this feature of balancing baseline
covariates across treatment groups. Rather, DRS seek to balance outcome determinants such
that baseline outcome risk is similar between treatment groups. In contrast to EPS, DRS are
not limited when exposure is rare or categorical, and they can provide a meaningful scale
across which investigators can examine effect modification. Despite their advantages and
even though they were initially proposed before EPS,5,13-15 DRS have received less
attention in the epidemiologic literature.16 We sought to systematically examine trends the
use and application of DRS as a confounder summary method.
METHODS
We conducted a systematic literature search to identify all English language articles that
utilized DRS confounder summary score methods in studies of humans. We searched the
MEDLINE database from 1965 to May 2011 with keyword terms: “disease$ risk$ score$”,
“summary$ risk$ score$”, “multivariate$ risk$ score$”, “confounder$ score$”, and
“Miettinen$ confounder$ score$”; it was important to include terms in quotations to avoid
inclusion of papers that may have used comorbidity indices, such as the Charlson Index,17 or
a risk scoring system, such as the Framingham risk score.18 We then used Web of Science®
to perform a citation search to identify papers that referenced seminal DRS method
papers,5,6,10,11 and an author search to identify articles published by investigators noted to
have frequently used DRS (PG Arbogast and WA Ray). Two authors (MT, JJG) reviewed
all abstracts to exclude articles that clearly did not meet eligibility criteria. Discrepancies
were resolved by agreement. Full text articles were then reviewed to confirm eligibility. The
number of eligible publications was plotted by calendar year and type, as: empirical
application, methodological contribution or review paper. We then focused exclusively on
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the empirical applications and abstracted: author, journal, year of publications, terminology
used to describe method, study design, sample size, exposure and outcome variable, number
of outcome events, primary analytical methods to derive DRS (statistical method used, data
type, number of covariates in model), and how DRS was applied. One author (MT) extracted
all data and a second author (JJG) verified all extracted data. The area of study and methods
of DRS derivation and application were tabulated overall, and stratified by calendar year of
publication in print (before or after January 2000).
RESULTS
Of 714 unique articles identified, 97 studies were eligible: 8 methodological
contributions,5-7,10-12,19,20 3 review papers,16,21,22 and 86 were empirical
applications,23-108Figure 1. We retained one abstract that had not yet been published in full
form,12 and excluded one abstract identified through the search that was recently published
in a full-text article.8,20 The keyword search identified 173 articles (20 relevant empirical),
the major paper citation search identified 338 articles (73 relevant empirical), and the author
search identified 320 articles (11 relevant empirical) – each method yielded unique
empirical papers, and no paper was identified by all three search methods, Figure 2. The
empirical studies were published between March 1976 and May 2010 with a bimodal
distribution; 32 (37%) articles were published prior to 1990, 15 (17%) in the 1990s, and 39
(45%) published since 2000 (Figure 3).
Table 1 summarizes the DRS derivation and application methods, with full details presented
for each paper in the online Appendix. The most common terminology used to describe
DRS methods included the words and/or combinations of: 1. summary, 2. confounder, 3.
Miettinen, and 4. score; and many included disease specific terminology. Cohort (47%) and
case-control (42%) studies were the most common study designs. Studies of cancer risk
(27%) and drug effects (24%) were the most common applications. Application focus
changed over time, with environmental and social exposures/outcomes (32%) and cancer
risk (19%) the most common before 2000 and drug exposures (46%) and skin cancer risk
(36%) dominating since 2000.
DRS methods were not clearly reported in up to 15 percent of empirical papers, Table 1. Of
the empirical papers reporting derivation methods, logistic regression (47%), followed by
discriminant analysis (17%) where the most common, with a shift away from discriminant
analysis and no study using this method since 2000. The majority of papers did not specify
the cohort used to derive DRS (70%). Of the 26 papers with methodological detail, 85%
created DRS in an “unexposed” or subgroup. DRS were most commonly used as a
categorical variable (93%), with a shift from stratification prior to 2000 (89% of applications
published before January 2000) to use as a covariate in regression models (63% of
applications) since January 2000. The most common number of groups were 3 (28%), 5
(28%), 4 (19%), and 10 (18%).
DISCUSSION
We examined use of DRS as a confounder summary score method over time and identified a
bimodal distribution in DRS application with a peak 1979-1980 and resurgence since 2000.
This bimodal distribution is not surprising given early simulation efforts. In 1976, Miettinen
proposed the creation of a ‘multivariate confounder score’ in the unexposed group to be
applied in the full cohort to examine exposure effects adjusted for confounding variables.5
However, early simulation work by Pike in 1979 concluded that the DRS method may
overestimate the effect of confounders and thus bias results.10 A subsequent simulation by
Cook and Goldman published in 1989 concluded that overestimation of confounders may be
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rare, particularly when applying the DRS as a categorical variable.11 These results likely
rejuvenated interest and confidence in the methodology. The increase since 2000 may also
partially relate to the recent increased demand and continued importance of comparative
effectiveness research, particularly in the area of pharmacoepidemiology,9,109,110 with 46
percent of DRS application papers related to drug safety and effectiveness since 2000.
Our results show great variation in DRS application with differences in methods of score
derivation, utilization, and naming. The most common method of DRS derivation was
originally discriminant analysis and since 2000, has been logistic regression. This follows
trends of analyses seen in the last 40 years of health science research with older studies
utilizing discriminant analysis, and more recent publications utilizing logistic and other
regression analyses. Miettinen's original derivation of the DRS used a discriminant function
and discussed Cox, logistic, and linear models as possible alternatives.5
About half (42%) of empirical studies applied DRS in a case-control study, however only
two methodological contributions have examined DRS using a case-control study
design.10,12 Pike completed his simulation work that halted wide uptake of the DRS using a
case-control study design,10 and a recent simulation published in abstract form concluded
that the DRS may be appropriate in the case-control study when exposure is not highly
correlated with its confounders.12 Use of the propensity score in a case-control has been
shown to introduce artificial effect modification and reduce control of confounding.111
Further methodological work is needed to support DRS utilization in the case-control
setting.
DRS were most commonly used as a categorical variable to control for confounding in the
main outcome model. The number of categories varied, with 3 (28%) and 5 (28%) groups
being the most common. Miettinen recommended that the initial analysis be completed with
equal deciles and then adjacent strata combined to create five strata.5 In many cases, the
most clinically relevant number of groups may be three with risk stratified into low, medium
and high. However, few studies used DRS to communicate results by disease strata (23%).
We believe this to be an underutilization of DRS benefits. The added advantage of graphical
presentation may allow for easier communication of results and identify effect modification
by baseline outcome risk. Stratifying results by disease risk strata may be particularly
beneficial in drug effects studies to maximize the benefits and limit harms in patients. Oral
bisphosphonates, as an example, are indicated to treat osteoporosis and reduce fracture risk
among patients with low bone mineral density and/or major risk factors for fracture.113
Treating patients at low fracture risk may increase potential harms, with little benefit on
fracture risk reduction. Prior evidence identifies little difference in fracture risk reduction
between osteoporosis therapies among patients in low risk strata.7,114 Interestingly, few
studies used matching on the DRS as the means to implement DRS, yet matching on EPS is
common.3,4,9 In the presence of heterogeneous treatment effects, matching on the DRS or
examining risk by DRS strata after adjusting for DRS in the regression, allows investigators
to estimate exposure effects in well-defined populations and examine effect modification by
disease (outcome) risk. Once treatment effect heterogeneity has been described,
standardization methods such as matching on the DRS, stratifying the Cox proportional
hazards model on DRS strata, or another method to adjust for the observed interaction in the
regression model may be used if an overall treatment effect estimate is needed.
Our results show that, where reported, DRS were most commonly derived in a subgroup of
the study population and then applied to the study population at large. These applications are
similar to the recommendations made by Miettinen and Cook et al..5,11 These authors
argued the importance of creating the score in the unexposed group so that exposure does
not bias the underlying risk of outcome. However, more recent empirical and simulation
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work has identified that DRS creation in the full cohort may be important in settings where
exposure is highly correlated with covariates.7,8 In other settings, such as in the context of
new therapeutic agents, deriving DRS in an external historical cohort may be
advantageous.115 Further research is needed to understand the relative advantages and
disadvantages of different DRS approaches.
Our systematic review is subject to some limitations. First, although we completed a 3-step
search, we recognize that due to the lack of standardized terminology to describe DRS
methods, we may have missed some relevant applications. Indeed, upon discussion of our
review with colleagues, five additional DRS applications were identified that were not found
through our comprehensive search – three were early applications,13-15 and two described
DRS as “propensity score” for the outcome.116,117 Although “propensity score” for the
outcome is technically correct, this terminology makes the identification and interpretation
of the DRS more challenging. Propensity Score became an official MeSH keyword heading
in 2010, defined as the conditional probability of exposure to a treatment given observed
covariates. As DRS applications increase, standardized terminology is recommended.
Descriptions such as the “multivariate risk score” and “confounder score” may be confusing
and vague, and therefore we encourage adoption of the recent terminology Disease Risk
Score. Disease risk score is descriptive of the technique and unique versus propensity score
and may thus minimize possible confusion between these two confounder summary score
methods. Despite the limitations of our search strategy, it was interesting to note that all
three search strategies (keyword, citation and author) captured different studies with only 18
of the 86 studies identified by two methods, and no paper identified by all three search
methods. The citation search found the largest number of papers, 73 of the 86 papers.
Despite potentially missing some applications, we feel our results and conclusions of the
general trends would remain.
Second, given the lack of transparency or detail in how DRS was derived or applied,
accurate description of some applications was difficult and supports our recommendation for
improved transparency and a move toward standardized terminology in future applications.
The great variation in the utilization of DRS highlights the need for further work. Additional
simulation work is important to support the best means to utilize DRS, particularly in the
case-control setting. Finally, although we summarized derivation methods, we did not
consider the process of variable selection or its appropriateness. Considerations for variable
selection in DRS are similar to those for EPS and a conventional multivariable regression
strategy -- variables measured before the start of exposure are risk factors for the outcome of
interest, i.e., are potential confounding variables.118-120
In summary, we identified an increase in DRS application, yet underutilization of DRS to
examine potential effect modification by disease risk. Comparative safety and effectiveness
research may benefit from DRS to help target interventions to those who benefit most.
However, more work is needed to guide DRS applications, particularly in the case-control
setting. A move towards better transparency in DRS derivation and utilization, and
standardization of terminology will facilitate DRS application and interpretation. We
recommend that future work consider utilizing the terminology Disease Risk Score when
describing confounder summary scores derived based on the primary outcome model.
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Key Points (5 max)
• Disease Risk Scores (DRS) are confounder summary scores derived based on
the probability of disease outcome and may be advantageous over other
confounding adjustment techniques when exposure is rare, to study multiple
exposures, and to study effect modification by outcome risk.
• Use of DRS confounder summary methods has increased, yet remains low. We
observed a bimodal distribution in the number of publications over time, with a
peak 1979-1980, and resurgence since 2000. Close to half of empirical
applications since 2000 have been associated with pharmacoepidemiology.
• Great variation in DRS application exist with differences in methods of score
derivation, utilization, and naming.
• There is a general lack of transparency in methods used to derive and apply
DRS methods, and few studies used DRS to its full potential by examining
effect modification by outcome risk.
• A move toward standardized terminology and providing methodological detail
will facilitate DRS utilization and interpretation. We recommend that future
work consider adopting the terminology Disease Risk Score when applying
confounder summary scores derived based on the probability of disease
outcome.
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Flow Diagram of Systematic Search Results
Tadrous et al. Page 14














Venn Diagram of Search Result Yield of Empirical Applications, by Search Strategy, N=86
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Number of Disease Risk Score Confounder Summary Score Publications, by Year of
Publication, N=97. Empirical application (solid, n=86), methodological contribution
(diagonal stripes, n=8) and review papers (horizontal stripe, n=3); 35 papers published
before 1990, 16 papers published between 1990 and 1999, and 46 papers published since
January 2000.
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